Literature DB >> 19303320

Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins.

Anne Tournadre1, Marine Porcherot, Patrick Chérin, Isabelle Marie, Eric Hachulla, Pierre Miossec.   

Abstract

To clarify the interactions between dendritic cells (DCs) and Th1 and Th17 T cell subsets and the mode of action of IVIG in inflammatory myopathies, Expression of CD4(+) and CD8(+) T cells, immature (CD1a) and mature (DC-LAMP) DCs, interleukin-17 (IL-17) and interferon-gamma (IFN-gamma), was quantified by immunohistochemistry in muscle biopsies from 13 patients (11 with polymyositis (PM) and 2 dermatomyositis (DM)) obtained before treatment with IVIG. The Th1/Th17 cytokine and the immature/mature DC ratio were studied according to the response to IVIG. Immature DCs were rarely detected compared to mature DCs, observed in all samples except one PM. IFN-gamma-producing cell count was higher than IL-17 count. Neither the expression of IFN-gamma nor IL-17 was correlated with that of DC subsets. Seven of the 13 patients (6 PM and 1 DM) responded to IVIG. T cells and DC subsets were not differentially expressed between responders and non-responders. The frequency of IFN-gamma-producing cells was significantly higher in non-responders with an increased IFN-gamma/IL-17-producing-cell ratio. In conclusion, mature rather than immature DC and IFN-gamma-rather than IL-17-producing cells accumulate in inflamed muscle. Increased IFN-gamma-producing cell count and IFN-gamma/IL-17-ratio were found in IVIG non-responders, suggesting a role for the Th17 mediated pathway in the response to IVIG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19303320     DOI: 10.1016/j.cyto.2009.02.013

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  16 in total

1.  CD4+ cells, macrophages, MHC-I and C5b-9 involve the pathogenesis of dysferlinopathy.

Authors:  Xi Yin; Qian Wang; Ting Chen; Junwei Niu; Rui Ban; Jiexiao Liu; Yanling Mao; Chuanqiang Pu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 2.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

3.  Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets.

Authors:  F Espinosa-Ortega; D Gómez-Martin; K Santana-De Anda; J Romo-Tena; P Villaseñor-Ovies; J Alcocer-Varela
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

Review 4.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

5.  Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis.

Authors:  Murat Giriş; Hacer Durmuş; Berrak Yetimler; Hatice Taşli; Yeşim Parman; Erdem Tüzün
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

6.  Ro52/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies.

Authors:  D Gómez-Martín; A S Galindo-Feria; A Barrera-Vargas; J Merayo-Chalico; G Juárez-Vega; J Torres-Ruiz; J Alcocer-Varela
Journal:  Clin Exp Immunol       Date:  2017-01-22       Impact factor: 4.330

Review 7.  Interleukin-17 in inflammatory myopathies.

Authors:  Anne Tournadre; Pierre Miossec
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 8.  A critical role for immature muscle precursors in myositis.

Authors:  Anne Tournadre; Pierre Miossec
Journal:  Nat Rev Rheumatol       Date:  2013-03-12       Impact factor: 20.543

Review 9.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

10.  Increased muscle expression of interleukin-17 in Duchenne muscular dystrophy.

Authors:  L De Pasquale; A D'Amico; M Verardo; S Petrini; E Bertini; F De Benedetti
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.